Multiple Myeloma: Molecular Imaging with 11C-Methionine PET/CT--Initial Experience.

PURPOSE To prospectively assess molecular imaging of multiple myeloma (MM) by using the radiolabeled amino acid carbon 11 ((11)C) methionine and positron emission tomography (PET)/computed tomography (CT). MATERIALS AND METHODS The study was approved by the institutional local ethics committee and the national radiation protection authorities. All patients with MM and control patients gave written informed consent. Nineteen patients with MM (11 women, eight men; age range, 42-64 years) and 10 control patients with hyperparathyroidism without hematologic diseases (six women, four men; age range, 43-75 years) underwent PET/CT 20 minutes after injection of a mean of 1.0 GBq +/- 0.2 (standard deviation) (11)C-methionine. Presence and extent of CT-assessed tumor manifestations and (11)C-methionine bone marrow (BM) uptake were determined on the basis of maximum standardized uptake value (SUV(max)). BM imaging patterns, normal BM, and maximal lesion (11)C-methionine uptake in patients with MM were compared with those in control patients. In two patients with MM, sulfur 35 ((35)S) methionine uptake in freshly isolated BM plasma cells was measured. Values for SUV(max) of groups were compared by using the Mann-Whitney test on a per-patient basis. RESULTS (35)S-methionine uptake of plasma cells was five- to sixfold higher than in normal BM cells. (11)C-methionine BM uptake in control patients was homogeneous and low. All patients with MM except one with exclusively extramedullary myeloma had (11)C-methionine-positive lesions. Maximal lesion and normal BM (11)C-methionine mean SUV(max) were 10.2 +/- 3.5 and 4.3 +/- 2.0, respectively, and thus were significantly higher than that of BM in the control group (mean, 1.8 +/- 0.3; P < .001). Extramedullary MM was clearly visible in three patients (mean SUV(max), 7.2 +/- 2.4). Additional (11)C-methionine-positive lesions in normal cancellous bone were found in nearly all patients with MM. In pretreated patients with MM, a moderate fraction of osteolytic lesions had no (11)C-methionine uptake. CONCLUSION On the basis of increased methionine uptake in plasma cells, active MM can be imaged with (11)C-methionine PET/CT.

[1]  M. Dimopoulos,et al.  Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Morgan,et al.  Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. , 2003, The hematology journal : the official journal of the European Haematology Association.

[3]  H. Döhner,et al.  Initial results in the assessment of multiple myeloma using 18F-FDG PET , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  R W Günther,et al.  Multidetector CT of the spine in multiple myeloma: comparison with MR imaging and radiography. , 2002, AJR. American journal of roentgenology.

[5]  H. Goldschmidt,et al.  Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma , 2003, British journal of haematology.

[6]  R. Bataille,et al.  Interleukin-6 is a growth factor for nonmalignant human plasmablasts. , 2001, Blood.

[7]  D. Comar,et al.  Labelling and metabolism of methionine-methyl-11C , 2004, European Journal of Nuclear Medicine.

[8]  S. Barrington,et al.  Fluoro‐deoxyglucose positron emission tomography imaging for the detection of occult disease in multiple myeloma , 2002, British journal of haematology.

[9]  B. Maldague,et al.  Skeletal survey in advanced multiple myeloma: radiographic versus MR imaging survey , 1999, British journal of haematology.

[10]  M. Reiser,et al.  Role of MRI for the diagnosis and prognosis of multiple myeloma. , 2005, European journal of radiology.

[11]  Gary Caputo,et al.  Value of FDG PET in the assessment of patients with multiple myeloma. , 2005, AJR. American journal of roentgenology.

[12]  P. Gaulard,et al.  Bone marrow with diffuse tumor infiltration in patients with lymphoproliferative diseases: dynamic gadolinium-enhanced MR imaging. , 2003, Radiology.

[13]  C. Metz ROC Methodology in Radiologic Imaging , 1986, Investigative radiology.

[14]  H. Schirrmeister,et al.  Positron emission tomography (PET) for staging of solitary plasmacytoma. , 2003, Cancer biotherapy & radiopharmaceuticals.

[15]  B. Barlogie,et al.  Multiple myeloma: clinical review and diagnostic imaging. , 2004, Radiology.

[16]  M. Reiser,et al.  Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? , 2002, Cancer.

[17]  Kenneth C. Anderson,et al.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group , 2003, British journal of haematology.

[18]  S. Jagannath,et al.  CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.

[19]  M. Coel,et al.  Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. , 2005, The Journal of urology.

[20]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.